Corbus Pharmaceuticals

CRBP · Nasdaq · United States

Share price · CRBP

$2.75-7.33 (-72.77%) 3M

close as of 2026-11-18 · 24h delayed · vol 635K (0.6x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when CRBP's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 17 Nov 2026-10.8%
  2. 12 Nov 2026-14.7%
  3. 10 Nov 2026+11.6%
  4. 9 Nov 2026+14.7%
  5. 5 Nov 2026-19.9%
  6. 4 Nov 2026-7.8%

    Nothing announced by CRBP that day or the session before.

  7. 15 Sep 2026-14.4%
  8. 9 Sep 2026-16.4%

    Nothing announced by CRBP that day or the session before.

  9. 26 May 2026-30.3%
  10. 21 May 2026+18.3%

Share of unusual movement by asset

For each asset, the share of CRBP's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Sutantatug envedotin
events and moves
2015%
CRB-913
events and moves
113%
Other company news (earnings, financing, releases naming no asset)—16%
Sessions with no dated event—66%

Assets

(2 total)
2Total Assets
0Approved
1Phase 3 / Filed
1Phase 1–2 / Early
3Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Phase 3
Nectin-4Antibody–drug conjugate
Cervical CancerBladder / Urothelial Cancer
Urothelial Carcinoma
Phase 1
CB1 receptorSmall molecule
Obesity

Upcoming events

(6 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (3)
January 2027 (1)
Sutantatug envedotinPhase 1/2Solid Tumor, Adult
Est. primary completion 2027-01-16 · NCT06265727 · CT.gov ↗
What to watch
December 2027 (2)
Sutantatug envedotinPhase 3Oropharyngeal Carcinoma (OPC)
Est. primary completion 2027-12 · NCT07768189 · CT.gov ↗
What to watch
Sutantatug envedotinPhase 2Head and Neck Squamous Cell Carcinoma
Est. primary completion 2027-12-30 · NCT06989671 · CT.gov ↗
What to watch
2028 (2)
January 2028 (1)
Sutantatug envedotinPhase 3Cervical Cancer
Est. primary completion 2028-01-01 · NCT07230626 · CT.gov ↗
What to watch
June 2028 (1)
Sutantatug envedotinPhase 2Advanced Urothelial Carcinoma
Est. primary completion 2028-06-01 · NCT07374549 · CT.gov ↗
What to watch
2029 (1)
June 2029 (1)
Sutantatug envedotinPhase 3Urothelial Carcinoma
Est. primary completion 2029-06-01 · NCT07526792 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

14 September 2026Topline resultCRB-913Phase 1b CANYON-1 topline of CRB-913 in obesity
Corbus Pharmaceuticals · Source ↗

Financial reports

Quarterly & interim (17)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3—$34M$30M+ $85M short-term inv.$38M-$21M operating cash flowreport ↗
View 16 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$31M$23M+ $95M short-term inv.$35M-$30M operating cash flowreport ↗
2026-Q1—$20M$26M+ $113M short-term inv.$23M-$26M operating cash flowreport ↗
2025-Q3—$21M$27M+ $77M short-term inv.$23M-$16M operating cash flowreport ↗
2025-Q2—$15M$20M+ $97M short-term inv.$18M-$17M operating cash flowreport ↗
2025-Q1—$16M$19M+ $114M short-term inv.$17M-$16M operating cash flowreport ↗
2024-Q3—$11M$19M+ $140M short-term inv.$14M-$14M operating cash flowreport ↗
2024-Q2—$6.9M$24M+ $123M short-term inv.$10M-$8.9M operating cash flowreport ↗
2024-Q1—$5.8M$14M+ $106M short-term inv.$6.9M-$8.0M operating cash flowreport ↗
2023-Q3—$6.5M$11M+ $17M short-term inv.$10M-$7.2M operating cash flowreport ↗
2023-Q2—$4.3M$8.3M+ $28M short-term inv.$8.8M-$7.8M operating cash flowreport ↗
2023-Q1—$13M$7.3M+ $37M short-term inv.$18M-$15M operating cash flowreport ↗
2022-Q3$0$4.1M$12M+ $54M short-term inv.$8.8M-$7.3M operating cash flowreport ↗
2022-Q2—$2.5M$26M+ $48M short-term inv.$13M-$12M operating cash flowreport ↗
2022-Q1$0$3.3M$57M+ $29M short-term inv.$9.4M-$11M operating cash flowreport ↗
2021-Q4—$0.4M$25M+ $73M short-term inv.—-$9.7M operating cash flowreport ↗
2021-Q3$0.1M$8.7M$37M+ $70M short-term inv.$2.2M$0.9M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY—$70M$28M+ $135M short-term inv.$20M-$64M operating cash flowreport ↗

Corbus Pharmaceuticals reported no revenue for fiscal year 2025. Research and development spending was $70.1M, up 117.6% YoY, while cash and equivalents stood at $28.49M. The company reported a net loss of $78.54M for the full year.

Management guided that existing cash is expected to fund operations into 2028. CRB-701 demonstrated encouraging Phase 1/2 efficacy data at ESMO 2025 in HNSCC, cervical, and bladder cancers, with monotherapy data expected in mid-2026 and a Keytruda combination readout in Q4 2026. CRB-913 showed 2.9% placebo-adjusted weight loss at 14 days with a favorable gastrointestinal safety profile, and the 12-week CANYON-1 obesity study (n=240) is scheduled to complete in summer 2026. The CRB-601 program was deprioritized, and a $75 million public offering closed in Q4 2025.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY—$32M$17M+ $132M short-term inv.$10M-$42M operating cash flowreport ↗
2023-FY—$31M$14M+ $7.2M short-term inv.$11M-$36M operating cash flowreport ↗
2022-FY$0$16M$17M+ $42M short-term inv.$11M-$38M operating cash flowreport ↗
2021-FY$0.9M$36M$25M+ $73M short-term inv.$11M-$48M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 3 purchases ($126K), 14 sales ($2.7M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-10-29Cormorant Asset Management, LP; Cormorant Global Healthcare Master Fund, LP; Chen Bihua · Former 10% Owner; Former 10% Owner; Former 10% OwnerOpen-market sale425,000$4.10$1.7MForm 4
2026-09-14Ben Yong · directorOpen-market sale2,000$7.84$16KForm 4
2026-08-16Nicacio Leonardo Viana · Chief Medical OfficerAward / grant58,333——Form 4
2026-08-16Nicacio Leonardo Viana · Chief Medical OfficerAward / grant (derivative)191,676——Form 4
2026-08-11Saxena Nishant C · Chief Business OfficerOpen-market purchase2,600$9.63$25KForm 4
2026-08-07Moran Sean F. · Chief Financial OfficerOpen-market sale12,000$10.08$121KForm 4
2026-08-07Cohen Yuval · director, Chief Executive OfficerOpen-market sale17,000$10.08$171KForm 4
2026-06-10Jenkins John Kenneth · directorOpen-market sale4,800$7.91$38KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 105 reporting institutions held 12.8M shares ($119.1M, 62.3% of shares outstanding).

#InstitutionSharesValue
1Cormorant Asset Management, LP2,344,971$22.0M
2ORBIMED ADVISORS LLC1,737,287$16.3M
3Aberdeen Group plc1,321,750$12.4M
4VANGUARD CAPITAL MANAGEMENT LLC734,106$6.9M
5CITADEL ADVISORS LLC727,060$6.8M
6Prosight Management, LP697,108$6.5M
7DIADEMA PARTNERS LP439,957$4.1M
8Stonepine Capital Management, LLC383,462$3.6M
9ARMISTICE CAPITAL, LLC364,000$3.4M
10RENAISSANCE TECHNOLOGIES LLC346,998$3.3M
11SUSQUEHANNA INTERNATIONAL GROUP, LLP333,415$3.1M
12ADAR1 Capital Management, LLC331,781$3.1M
13BlackRock, Inc.271,636$2.6M
14Exome Asset Management LLC234,136$2.2M
15GEODE CAPITAL MANAGEMENT, LLC187,029$1.8M